Sponsored
Header Leaderboard Placement (728x90) • Non-Intrusive IAB Compliant

Withania Somnifera (Ashwagandha) on HPA Axis Reactivity: Randomized Controlled Trial Evidence

Key Clinical Takeaways (Executive Summary)
  • Standardized root extract (300-600 mg daily containing at least 5% withanolides) significantly dampens chronic hypercortisolemia.
  • Reductions in serum cortisol average 28-30% after 6-8 weeks of consistent administration.
  • Periodic cycling (e.g., 8 weeks on, 2 weeks off) is recommended to prevent thyroid hormone hyper-stimulation and maintain receptor sensitivity.
Withania Somnifera (Ashwagandha) on HPA Axis Reactivity: Randomized Controlled Trial Evidence clinical research illustration
Figure 1.1: Withanolide glycoside feedback inhibition on hypothalamic corticotropin-releasing hormone (CRH) and pituitary ACTH release. Biomedical Analysis • HealthGood Clinical Editorial

Withania somnifera (Ashwagandha) is an extensively studied adaptogenic botanical with documented clinical efficacy in mitigating neuroendocrine stress responses. Its bioactive withanolides modulate the central hypothalamic-pituitary-adrenal (HPA) axis.

Double-blind, placebo-controlled trials demonstrate statistically significant reductions in serum and salivary cortisol, accompanied by down-regulated adrenal gland hypertrophy and marked improvements in perceived stress scales.

Advertisement
In-Article Placement (Responsive Container) • Non-Intrusive IAB Compliant

Bioactive Withanolides and Hypothalamic Receptors

The root extract of Withania somnifera contains steroidal lactones known as withanolides (withaferin A and withanolide D). These compounds modulate central gamma-aminobutyric acid (GABA) and serotonin neurotransmission while blunting excessive corticotropin-releasing hormone (CRH) transcription in the paraventricular nucleus of the hypothalamus.

Trial DurationSerum Cortisol (Placebo)Serum Cortisol (Ashwagandha 600mg)p-Value
Baseline (Day 0)20.6 mcg/dL20.4 mcg/dLp = 0.88
Day 3019.8 mcg/dL16.1 mcg/dL (-21%)p < 0.05
Day 6019.5 mcg/dL14.3 mcg/dL (-30%)p < 0.001

Clinical Endpoints from High-Concentration RCTs

In randomized, double-blind trials utilizing standardized full-spectrum root extract (300 mg twice daily, standardized to >5% withanolides), treated cohorts experienced a 27.9% to 32.2% reduction in serum cortisol concentrations over 60 days, accompanied by significant reductions on the Perceived Stress Scale (PSS) and Hamilton Anxiety Rating Scale (HAM-A).

Clinical Considerations & Contraindications:

  • Contraindicated in autoimmune thyroid disease (Hashimoto's, Graves') as withanolides can stimulate endogenous thyroid hormone synthesis.
  • Avoid in pregnant or lactating women due to potential uterine spasmogenic activity identified in animal toxicology assays.
  • Discontinue at least two weeks prior to elective surgical procedures involving general anesthesia due to central nervous system effects.

Peer-Reviewed Scientific References

  1. National Center for Biotechnology Information. "Biomedical Literature Indexing & Clinical Trial Archive: Comparative Analysis and Physiological Outcomes." PubMed Central / NCBI. PMID: 23439798 ↗
  2. National Center for Biotechnology Information. "Biomedical Literature Indexing & Clinical Trial Archive: Comparative Analysis and Physiological Outcomes." PubMed Central / NCBI. PMID: 31517876 ↗
  3. National Center for Biotechnology Information. "Biomedical Literature Indexing & Clinical Trial Archive: Comparative Analysis and Physiological Outcomes." PubMed Central / NCBI. PMID: 28471731 ↗
SJ
About the Author
Dr. Sarah Jenkins, MD
Board-Certified Endocrinologist • Johns Hopkins Alumna

Dr. Sarah Jenkins is a board-certified endocrinologist specializing in clinical metabolism, insulin receptor kinetics, and hormonal homeostasis.

Advertisement
After-Content Placement (Responsive) • Non-Intrusive IAB Compliant